305090.Kq

The company's capital structure is characterized by a debt-to-equity ratio of 0.8, indicating a moderate reliance on debt financing. Despite holding significant cash and equivalents of KRW 16,267,844,570, the company's liquidity is assessed as medium due to a negative net cash position after subtracting total debt. The current ratio of 2.36 suggests the company has sufficient short-term assets to cover its short-term liabilities. However, the operating cash flow of -KRW 5,619,899,130 and free cash flow of -KRW 18,678,765,220 indicate a lack of positive cash generation from operations.

Profitability metrics are severely negative, with a return on equity of -45.4% and a return on assets of -20.16%. These figures are well below the industry norms for medical equipment and supplies companies, which typically exhibit positive returns on equity and assets. The company's operating income of -KRW 9,130,599,060 and net income of -KRW 13,145,531,680 further underscore the financial distress. Gross profit of KRW 3,639,225,210 is insufficient to cover operating expenses, contributing to the significant losses.

The company's revenue concentration is not disclosed in the available data, but the absence of segment or geographic breakdowns suggests a lack of diversification in its revenue streams. This could pose a risk if the company is overly dependent on a single market or product line. The capital expenditure of -KRW 7,877,868,540 indicates ongoing investment in infrastructure or equipment, but the negative value suggests these expenditures are not being offset by positive cash flows.

The company's growth trajectory is uncertain, as the available data does not provide forward-looking revenue projections or outlooks. The current financial performance, marked by significant losses and negative cash flows, does not support a positive growth narrative. The lack of analyst recommendations other than one "strong buy" and the uniform price target of 28,000 KRW suggest limited confidence in the company's near-term prospects.

Risk factors include the company's negative net cash position and the high level of debt relative to equity. The risk assessment indicates a medium liquidity risk and a low dilution risk. The dilution potential is low, as the number of shares outstanding for both basic and diluted scenarios is the same, suggesting no imminent share issuance. However, the company's financial distress could lead to future dilution if it requires additional capital to fund operations or reduce debt.

Recent events, such as filings or transcripts, are not detailed in the available data. The company's financial snapshot and risk assessment suggest a need for close monitoring of its liquidity and profitability trends. Analysts have provided a uniform price target of 28,000 KRW, but the lack of varied recommendations indicates a cautious outlook.